Cell cycle modulatory and apoptotic effects of plant-derived anticancer drugs in clinical use or development

被引:24
作者
Darwiche, Nadine [1 ]
El-Banna, Sara [1 ]
Gali-Muhtasib, Hala [1 ]
机构
[1] Amer Univ Beirut, Dept Biol, Beirut, Lebanon
关键词
anticancer; apoptosis; cell cycle; plant;
D O I
10.1517/17460441.2.3.361
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Drugs derived from natural products, particularly from plants, are the leads of clinically used anticancer agents. Plant-derived anticancer agents in clinical use consist of the Vinca alkaloids, vinblastine and vincristine, camptothecin derivatives, paclitaxel, etoposide and teniposide, homoharringtonine and elliptinium. Extensive research has led to the identification of promising plant-derived anticancer agents in clinical development, namely flavopiridol, combretastatins and roscovitine. These compounds share common antitumor activities and signaling pathways targeting tumor cell cycle and cell death. This review presents the discovery of plant-derived anticancer agents, their biologic activities, with emphasis on cell cycle and apoptotic effects and combination strategies for treatment optimization.
引用
收藏
页码:361 / 379
页数:19
相关论文
共 199 条
[41]   Cellular FLICE-like inhibitory protein (c-FLIP): A novel target for Taxol-induced apoptosis [J].
Day, Travis W. ;
Najafi, Farhad ;
Wu, Ching-Huang ;
Safa, Ahmad R. .
BIOCHEMICAL PHARMACOLOGY, 2006, 71 (11) :1551-1561
[42]   Inhibition of cyclin-dependent kinases by purine analogues - Crystal structure of human cdk2 complexed with roscovitine [J].
DeAzevedo, WF ;
Leclerc, S ;
Meijer, L ;
Havlicek, L ;
Strnad, M ;
Kim, SH .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1997, 243 (1-2) :518-526
[43]   Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor [J].
Demidenko, ZN ;
Blagosklonny, MV .
CANCER RESEARCH, 2004, 64 (10) :3653-3660
[44]   ENDOTHELIAL CELL-PROLIFERATION AS A NOVEL-APPROACH TO TARGETING TUMOR-THERAPY [J].
DENEKAMP, J .
BRITISH JOURNAL OF CANCER, 1982, 45 (01) :136-139
[45]   Key factors in the rising cost of new drug discovery and development [J].
Dickson, M ;
Gagnon, JP .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (05) :417-429
[46]  
Duflos Alain, 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P55, DOI 10.2174/1568011023354452
[47]  
Ehrlichová M, 2005, ANTICANCER RES, V25, P4215
[48]   Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1α accumulation and activity by disrupting microtubule function [J].
Escuin, D ;
Kline, ER ;
Giannakakou, P .
CANCER RESEARCH, 2005, 65 (19) :9021-9028
[49]   Markedly diminished drug resistance-inducing properties of vinflunine (20′,20′-difluoro-3′,4′-dihydrovinorelbine) relative to vinorelbine, identified in murine and human tumour cells in vivo and in vitro [J].
Etiévant, C ;
Kruczynski, A ;
Barret, JM ;
Tait, AS ;
Kavallaris, M ;
Hill, BT .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 48 (01) :62-70
[50]  
Fan MY, 2000, CANCER RES, V60, P6403